ABC
La nefrite IgA
FRANCO PANIZON
Professore Emerito, Dipartimento di Scienze della Riproduzione e dello Sviluppo, Università di Trieste
Aprile 2004 - pagg. 251 -252
Parole chiave
Suggerite dall'AI
IT
Ematuria
Classificazione MeSH
Bibliografia
1. Julian BA, Wald FB, Rifai A, Mestcky J. IgA
nephropathy, the most common glomerulonephritis
worldwide: a neglected disease in
the United States. Am J Med 1988;84:129.
2. D’Amico G. The commonest glomerulonephritis in the World. IgA nephropathy. QJ Med 1987;245:709.
3. Donadio JV, Grande JP. IgA nephropathy. N Engl J Med 2002;347:738.
4. Radford MG jr, Donadio JV jr, Bergstrahl EJ, Grande JP. Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol 1997; 8:199.
5. Alamartine E, Sabatier JC, Guerin C, et al. Prognostic factors in mesangial IgA glomerulonephritis: an extensive study with univariate and multivariate analyses. Am J Kidney Dis 1991;18:12.
6. Galla JH. IgA nephropathy. Kidney Int 1995;47:337.
7. Bene MC, Faure GC. Mesangial IgA in IgA nephropathy arises from the mucosa. Am J Kidney Dis 1988;12:406.
8. Julian BA, Tomana M, Novak J, Mestecky J. Progress in the pathogenesis of IgA nephropathy. Adv Nephrol Necker Hosp 1999; 29:53.
9. Mesteky J, Tomana M, Crowley-Nowick PA, et al. Defective galactosylation and clearance of IgA1 molecules as a possible etiopathogenetic factor in IgA nephropathy. Contrib Nephrol 1993;104:172.
10. Meadow SR, Scott DG. Berger Disease: Henoch-Schoenlein Syndrome without the rash. J Pediatr 1985;106:27.
11. Rena G, Begg F, Ross A, et al. Molecular cloning, genomic positioning, promoter identification and characterization of the novel cyclic AMP-specific phosphodiesterase PDEAA10. Mol Pharmacol 2001;59:996.
12. Hamazaki T, Tateno S, Sishido H. Eikosapentaenoic acid and IgA nephropathy. Lancet 1984;1:1017.
13. Donadio JV jr Bergstrahl EJ, Offord KP, et al. A controlled trial of fish oil in IgA nephropathy. N Engl J Med 1994;331:1194.
14. Grande JP Walker HJ, Holun BJ, et al. Suppressive effects of fish oil on mesangial cell proliferation in vitro and in vivo. Kidney Int 2000;57:1027.
15. Ruso D, Pisani A, Balletta MM, et al. Additive antiproteinuric effect of converting enzyme inhibitory and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 1999;33:551.
16. Pozzi C, Bolasco PG, Fogazzi GB, et al. Corticosteroids in IgA nephropathy. A randomized controlled trial. Lancet 1999;353:883.
17. Bene MC, Hurault de Ligny B, Kessler M, et al. Tonsills in IgA nephropathy. Contrib Nephrol 1993;104:153.
18. Rasche FM, Schwarz A, Keller F. Tonsillectomy does not prevent a progressive course of IgA nephropathy. Clin Nephrol 1999;51: 147.
2. D’Amico G. The commonest glomerulonephritis in the World. IgA nephropathy. QJ Med 1987;245:709.
3. Donadio JV, Grande JP. IgA nephropathy. N Engl J Med 2002;347:738.
4. Radford MG jr, Donadio JV jr, Bergstrahl EJ, Grande JP. Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol 1997; 8:199.
5. Alamartine E, Sabatier JC, Guerin C, et al. Prognostic factors in mesangial IgA glomerulonephritis: an extensive study with univariate and multivariate analyses. Am J Kidney Dis 1991;18:12.
6. Galla JH. IgA nephropathy. Kidney Int 1995;47:337.
7. Bene MC, Faure GC. Mesangial IgA in IgA nephropathy arises from the mucosa. Am J Kidney Dis 1988;12:406.
8. Julian BA, Tomana M, Novak J, Mestecky J. Progress in the pathogenesis of IgA nephropathy. Adv Nephrol Necker Hosp 1999; 29:53.
9. Mesteky J, Tomana M, Crowley-Nowick PA, et al. Defective galactosylation and clearance of IgA1 molecules as a possible etiopathogenetic factor in IgA nephropathy. Contrib Nephrol 1993;104:172.
10. Meadow SR, Scott DG. Berger Disease: Henoch-Schoenlein Syndrome without the rash. J Pediatr 1985;106:27.
11. Rena G, Begg F, Ross A, et al. Molecular cloning, genomic positioning, promoter identification and characterization of the novel cyclic AMP-specific phosphodiesterase PDEAA10. Mol Pharmacol 2001;59:996.
12. Hamazaki T, Tateno S, Sishido H. Eikosapentaenoic acid and IgA nephropathy. Lancet 1984;1:1017.
13. Donadio JV jr Bergstrahl EJ, Offord KP, et al. A controlled trial of fish oil in IgA nephropathy. N Engl J Med 1994;331:1194.
14. Grande JP Walker HJ, Holun BJ, et al. Suppressive effects of fish oil on mesangial cell proliferation in vitro and in vivo. Kidney Int 2000;57:1027.
15. Ruso D, Pisani A, Balletta MM, et al. Additive antiproteinuric effect of converting enzyme inhibitory and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 1999;33:551.
16. Pozzi C, Bolasco PG, Fogazzi GB, et al. Corticosteroids in IgA nephropathy. A randomized controlled trial. Lancet 1999;353:883.
17. Bene MC, Hurault de Ligny B, Kessler M, et al. Tonsills in IgA nephropathy. Contrib Nephrol 1993;104:153.
18. Rasche FM, Schwarz A, Keller F. Tonsillectomy does not prevent a progressive course of IgA nephropathy. Clin Nephrol 1999;51: 147.